<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">Messenger RNA (mRNA) vaccines carry transcripts encoding antigens, and use the host cell translational machinery to produce the antigens, which then stimulates an immune response
 <xref rid="bib65" ref-type="bibr">
  <sup>65</sup>
 </xref>. Because of high yields of 
 <italic>in vitro</italic> transcription reactions, mRNA has the potential for rapid, inexpensive and scalable manufacturing, which greatly shortens the development time and can respond quickly to epidemics. Compared to DNA vaccines, mRNA vaccines do not need to pass an additional membrane barrier (nuclear membrane), so it does not have safety concerns about integration into the host genome
 <xref rid="bib66" ref-type="bibr">
  <sup>66</sup>
 </xref>. Due to the above advantages, mRNA vaccines are becoming a powerful tool against coronavirus infection.
</p>
